PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35231655-6	2022	Conversely, pharmacological activation of Wnt10b-beta-catenin signaling by LiCl suppressed NR_015556 KD-induced enhancement of adipocyte differentiation and Ppar-gamma and C/EBPalpha expression levels.	Lithium Chloride	75-79	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	172-182	
24091675-6	2013	We further found that the Wnt/beta-catenin pathway is involved in Dex-induced osteoporosis and C/EBPalpha promoter methylation, and its activation by LiCl rescues the effect of Dex on C/EBPalpha promoter methylation and osteoblast/adipocyte balance.	Lithium Chloride	150-154	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	184-194	
12668682-5	2003	GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation.	Lithium Chloride	70-74	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	16-26	
12668682-5	2003	GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation.	Lithium Chloride	70-74	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	135-145	
12668682-5	2003	GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation.	Lithium Chloride	70-74	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	135-145	
12668682-5	2003	GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation.	Lithium Chloride	70-74	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	135-145	
12668682-5	2003	GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation.	Lithium Chloride	70-74	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	135-145	
12668682-6	2003	However, a mutant C/EBPalpha containing T to A mutations in the GSK3 phosphorylation sites (T222A and T226A) retained its response to LiCl, and additional pharmacological inhibitors of GSK3 did not alter C/EBPalpha levels indicating the effects of LiCl on C/EBPalpha are GSK3-independent.	Lithium Chloride	134-138	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	18-28	
12668682-6	2003	However, a mutant C/EBPalpha containing T to A mutations in the GSK3 phosphorylation sites (T222A and T226A) retained its response to LiCl, and additional pharmacological inhibitors of GSK3 did not alter C/EBPalpha levels indicating the effects of LiCl on C/EBPalpha are GSK3-independent.	Lithium Chloride	248-252	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	18-28	
12668682-7	2003	LiCl treatment of BALB/MK2 cells inhibited C/EBPalpha degradation and produced a 6-fold increase in the half-life of C/EBPalpha protein.	Lithium Chloride	0-4	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	43-53	
12668682-7	2003	LiCl treatment of BALB/MK2 cells inhibited C/EBPalpha degradation and produced a 6-fold increase in the half-life of C/EBPalpha protein.	Lithium Chloride	0-4	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	117-127	
12668682-8	2003	In vitro studies revealed that LiCl inhibited proteasome activity and the ensuing degradation of C/EBPalpha.	Lithium Chloride	31-35	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	97-107